Form 4: Cabaletta Bio CEO Steven Nichtberger Acquires 450,000 Stock Options
SEC Form 4 Filing
Steven Nichtberger, CEO of Cabaletta Bio, Inc., reports the acquisition of 450,000 stock options at an exercise price of $1.67 on March 3, 2025.
Summary
- Steven Nichtberger, the President and CEO of Cabaletta Bio, Inc., filed a Form 4 on March 4, 2025.
- The report details the acquisition of 450,000 stock options on March 3, 2025, with an exercise price of $1.67 per share.
- These options vest over time, with 25% becoming exercisable on March 3, 2026, and the remainder vesting in equal quarterly installments over the following three years, contingent upon continued service.
- Following the transaction, Nichtberger directly owns 450,000 derivative securities (stock options).
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard executive compensation disclosure. The acquisition of stock options is generally viewed as a positive sign, aligning management's interests with shareholders, but it's not a guarantee of future performance.
Positives
- The acquisition of stock options by the CEO could align his interests with those of the shareholders, incentivizing him to improve the company's performance.
Future Outlook
The vesting schedule of the options suggests a long-term commitment from the CEO to the company's success.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.
Comparison to Industry Standards
- Stock option grants are a typical component of executive compensation packages in the biotech industry, similar to companies like Juno Therapeutics (acquired by Celgene) and Kite Pharma (acquired by Gilead).
- The vesting schedule, with a cliff followed by quarterly vesting, is also standard practice.
- The size of the grant should be compared to grants made to CEOs of similarly sized biotech companies to assess its relative value.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive sign, aligning the CEO's interests with the company's long-term success.
Key Dates
| Date | Description |
|---|---|
| 03/03/2025 | Date of the stock option transaction. |
| 03/03/2026 | Date when 25% of the stock options become exercisable. |
| 03/02/2035 | Expiration date of the stock options. |
| 03/04/2025 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.